High Throughput Screening (HTS)

Global High Throughput Screening (HTS) Market to Reach US$45.3 Billion by 2030

The global market for High Throughput Screening (HTS) estimated at US$42.9 Billion in the year 2024, is expected to reach US$45.3 Billion by 2030, growing at a CAGR of 0.9% over the analysis period 2024-2030. Consumables / Reagents, one of the segments analyzed in the report, is expected to record a 3.2% CAGR and reach US$16.9 Billion by the end of the analysis period. Growth in the Consumables/Reagents segment is estimated at 6.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.2 Billion While China is Forecast to Grow at 5.4% CAGR

The High Throughput Screening (HTS) market in the U.S. is estimated at US$11.2 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$11.3 Billion by the year 2030 trailing a CAGR of 5.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of -3.4% and 0.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately -2.0% CAGR.

Global High Throughput Screening (HTS) Market - Key Trends and Drivers Summarized

High Throughput Screening (HTS) has become a cornerstone methodology in pharmaceutical development and academic research, providing an efficient approach to identifying lead compounds that might evolve into new drugs. Utilizing automation, sophisticated software, and extensive chemical libraries, HTS facilitates the rapid evaluation of numerous compounds against biological targets, mainly proteins, which play critical roles in cellular processes. Introduced in the late 1980s, HTS gained prominence by expediting natural product screenings at major pharmaceutical companies and has expanded its application across various sectors including clinical diagnostics and industrial biotechnology. The ability to quickly sift through millions of compounds and identify those with potential therapeutic effects is invaluable in accelerating the pace of drug discovery. This screening method is versatile, allowing both in vitro and in vivo settings to assess compounds, thereby enabling the discovery of modulators of cellular or physiological endpoints without prior detailed knowledge of the target.

HTS is particularly effective in targeting enzymes due to their significance in disease pathways and as drug targets. Enzymes like kinases, which are involved in many cellular processes and diseases, including cancer and inflammatory disorders, are frequent targets in HTS campaigns. The primary detection methods in these screenings often use fluorescence-based assays, which, despite their high sensitivity, are prone to interference and false positives. To mitigate these issues, HTS assays are designed with specific considerations, such as the inclusion of detergents to avoid aggregates that cause misleading results. Once an assay is developed and validated, HTS can be scaled to a primary screening format using modern automation platforms. This phase integrates robotics, sophisticated liquid handling devices, and sensitive detectors, ensuring that the screenings are conducted efficiently and effectively. The process from hit identification to lead optimization involves scrutinizing compounds for key drug properties such as absorption, distribution, metabolism, excretion (ADME), and toxicity, underscoring HTS`s critical role in the early stages of drug discovery.

The evolution of HTS continues with technological and scientific advancements shaping its methodologies and increasing its impact and efficiency. The integration of artificial intelligence and machine learning enhances data analysis capabilities, allowing for a deeper interpretation of complex datasets. Innovations in assay technology, such as the adoption of microchip-based systems and nanoliter dispensing technologies, are refining the precision and reducing the resource requirements of screenings. The major drivers of growth in HTS include advancements in automation and robotics, the use of microfluidics and nanotechnology, and the increasing demand for personalized medicine, which relies on HTS for identifying unique biomarkers and developing tailored therapies. Moreover, the expansion of biologics and specialty pharmaceuticals, along with supportive regulatory environments and increased funding for drug discovery, are bolstering the adoption of HTS. Collaborations between academia and the pharmaceutical industry are also vital, facilitating knowledge exchange and enhancing the implementation of HTS technologies, particularly critical in responding to global health crises and the public demand for rapid development of effective medications.

SCOPE OF STUDY:

The report analyzes the High Throughput Screening (HTS) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Product Type (Consumables / Reagents, Instruments, Software & Services); Technology (Cell-based Assay, Label-Free Technology, Other Technologies); Application (Target Identification & Validation, Primary & Secondary Screening, Toxicology Assessment, Other Applications); End-Use (Pharmaceutical & Biotechnology Companies, Academic & Government Institutes, Contract Research Organizations (CRO), Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Agilent Technologies, Inc.
• Aurora Biomed Inc.
• Axxam SpA
• BD Biosciences
• Beckman Coulter Inc.
• Bio-Rad Laboratories Inc.
• BioTek Instruments Inc.
• BMG LABTECH GmbH
• Charles River Laboratories International Inc.
• Corning Inc.
• Danaher Corporation
• Evotec AG
• F. Hoffmann-La Roche Ltd.
• Genedata AG
• IntelliCyt® Corporation
• Luminex Corporation
• Molecular Devices Inc.
• Pall ForteBio LLC
• PerkinElmer Inc.
• Sigma-Aldrich Corp.
• Tecan Group Ltd.
• Thermo Fischer Scientific Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.